SBIO vs. ARKG
Compare and contrast key facts about ALPS Medical Breakthroughs ETF (SBIO) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
SBIO and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SBIO or ARKG.
Key characteristics
| SBIO | ARKG | |
|---|---|---|
| YTD Return | 27.70% | -21.08% |
| 1Y Return | 78.33% | 7.99% |
| 3Y Return (Ann) | -3.88% | -30.28% |
| 5Y Return (Ann) | 3.30% | -2.50% |
| Sharpe Ratio | 2.33 | 0.08 |
| Sortino Ratio | 3.05 | 0.43 |
| Omega Ratio | 1.36 | 1.05 |
| Calmar Ratio | 1.09 | 0.04 |
| Martin Ratio | 8.43 | 0.15 |
| Ulcer Index | 8.12% | 21.95% |
| Daily Std Dev | 29.37% | 40.68% |
| Max Drawdown | -63.06% | -80.10% |
| Current Drawdown | -33.74% | -76.83% |
Correlation
The correlation between SBIO and ARKG is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
SBIO vs. ARKG - Performance Comparison
In the year-to-date period, SBIO achieves a 27.70% return, which is significantly higher than ARKG's -21.08% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
SBIO vs. ARKG - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
SBIO vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
SBIO vs. ARKG - Dividend Comparison
SBIO's dividend yield for the trailing twelve months is around 0.17%, while ARKG has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 0.17% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% |
Drawdowns
SBIO vs. ARKG - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for SBIO and ARKG. For additional features, visit the drawdowns tool.
Volatility
SBIO vs. ARKG - Volatility Comparison
The current volatility for ALPS Medical Breakthroughs ETF (SBIO) is 7.51%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 9.92%. This indicates that SBIO experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.